← Back to Screener
Spero Therapeutics, Inc. Common Stock (SPRO)
Price$2.83
Value ScoreB
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)9.29%
Price vs S&P 500 (4W)9.14%
VGM Score63.34
Market Capitalization$163.86M
P/E Ratio (Annual)19.12x
All Metrics
Book Value / Share (Quarterly)$0.91
P/TBV (Annual)0.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.68%
Cash Flow / Share (Quarterly)$0.13
Price vs S&P 500 (YTD)10.53%
Net Profit Margin (TTM)24.90%
EPS (TTM)$0.17
10-Day Avg Trading Volume0.89M
EPS Excl Extra (TTM)$0.17
Revenue Growth (5Y)48.25%
EPS (Annual)$0.15
ROI (Annual)14.52%
Net Profit Margin (5Y Avg)-137.28%
Cash / Share (Quarterly)$0.97
P/E Basic Excl Extra (TTM)10.76x
Revenue Growth QoQ (YoY)-95.61%
P/E Normalized (Annual)19.12x
ROA (Last FY)12.44%
Revenue Growth TTM (YoY)37.24%
EBITD / Share (TTM)$0.23
ROE (5Y Avg)-55.12%
Operating Margin (TTM)22.08%
Cash Flow / Share (Annual)$-0.22
P/B Ratio3.10x
P/B Ratio (Quarterly)2.56x
Net Income / Employee (Annual)$342,900
EV / Revenue (TTM)1.76x
Net Interest Coverage (TTM)-79.03x
ROA (TTM)24.95%
EV / EBITDA (TTM)7.98x
EPS Incl Extra (Annual)$0.15
Current Ratio (Annual)7.59x
Quick Ratio (Quarterly)10.23x
3-Month Avg Trading Volume0.45M
52-Week Price Return32.86%
P/E Incl Extra (TTM)10.76x
Revenue / Employee (TTM)$2,447,400
Tangible BV / Share (Quarterly)$1.01
P/S Ratio (Annual)2.45x
Asset Turnover (Annual)0.97x
52-Week High$3.22
Operating Margin (5Y Avg)-138.01%
EPS Excl Extra (Annual)$0.15
Tangible BV CAGR (5Y)-2.14%
26-Week Price Return25.22%
Quick Ratio (Annual)7.40x
13-Week Price Return28.05%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.50x
Enterprise Value$107.73M
Revenue / Share Growth (5Y)22.11%
Asset Turnover (TTM)1.00x
Book Value / Share Growth (5Y)-25.34%
Revenue / Employee (Annual)$2,672,100
Pretax Margin (Annual)13.22%
Cash / Share (Annual)$0.71
3-Month Return Std Dev52.68%
Net Income / Employee (TTM)$609,400
ROE (Last FY)14.52%
Net Interest Coverage (Annual)-52.52x
EPS Basic Excl Extra (Annual)$0.15
P/FCF (TTM)4.92x
Receivables Turnover (TTM)7.37x
EV / Free Cash Flow (TTM)14.88x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.17
Receivables Turnover (Annual)28.73x
ROI (TTM)35.58%
P/S Ratio (TTM)2.68x
Pretax Margin (5Y Avg)-136.71%
Revenue / Share (Annual)$1.13
Tangible BV / Share (Annual)$1.45
Forward P/E4.03x
Price vs S&P 500 (52W)4.66%
P/E Ratio (TTM)10.76x
Year-to-Date Return21.46%
5-Day Price Return2.54%
EPS Normalized (Annual)$0.15
ROA (5Y Avg)-25.35%
Net Profit Margin (Annual)12.83%
Month-to-Date Return12.75%
Cash Flow / Share (TTM)$-0.02
EBITD / Share (Annual)$0.11
Operating Margin (Annual)9.45%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)22.63x
ROI (5Y Avg)-47.92%
P/E Excl Extra (TTM)10.76x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.17
P/TBV (Quarterly)1.17x
P/B Ratio (Annual)2.22x
Pretax Margin (TTM)25.33%
Book Value / Share (Annual)$1.05
Price vs S&P 500 (13W)18.31%
Beta1.45x
Revenue / Share (TTM)$1.07
ROE (TTM)35.58%
52-Week Low$1.80
vGradeB
gGradeC
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.13est. -0.18
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SPROSpero Therapeutics, Inc. Common Stock | B | C | B | $2.83 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Spero Therapeutics is a clinical-stage biopharmaceutical company developing novel antibiotics for multi-drug-resistant bacterial infections and rare diseases. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic for MDR Gram-negative infections; SPR720 for non-tuberculous mycobacterial infections; and SPR206, an intravenous polymyxin candidate for hospital-acquired MDR Gram-negative infections.